RESEARCH TRIANGLE PARK – The firm’s mission is to alleviate suffering from late-stage glaucoma, and now it’s got a name to match.
The former Camras Vision, a Durham medical device startup, has changed its name to Alievio “as part of a rebranding effort to further position the company as a leader in innovative glaucoma treatment solutions.
Alievio, Inc.
The rebranding includes a newly designed website, logo and communication assets.
Glaucoma is a leading cause of irreversible blindness worldwide, affecting 4 million in the United States and a projected 80 million people worldwide by 2020, according to the Glaucoma Research Foundation.
Alievio is currently developing a new device as the “first personalized glaucoma treatment to stop vision loss,according to its website.
Back in April 2018, WRAL TechWire reported that the company completed its $5.7 million Series A funding. At the time, it also announced that it would be seeking a Series B funding in 2019 of around $15 million.
“As Alievio’s device progresses towards commercialization, the company intends to generate awareness about glaucoma treatment for those late-stage patients who have failed to find relief and slow the progression of the disease with existing treatment options,” the company said in a statement.
